Concentrate of Autologous Rich Plasma in Growth Factors in the Treatment of the Thin Endometrium

Efficacy and Safety of the Concentrate of Autologous Rich Plasma in Growth Factors in the Treatment of the Thin Endometrium in Patients Undergoing Transfer of Cryo-preserved Embryos: Clinical Trial II.

This study evaluate the percentage of women with thin endometrium who achieve an endometrial thickness equal to or greater than 7 mm after administration of PRGF (plasma rich in growth factors)

Inclusion Criteria:

• Women who signed informed consent.
• Women who understand the Spanish language.
• Women under 42 years

Exclusion Criteria:

• Thrombopenia.
• Congenital or acquired uterine malformations that reduce embryo implantation or term gestation.
• Ovarian tumors.
• Benign uterine tumors require surgical treatment
• Local acute inflammatory diseases
• Patients with malignant tumors requiring chemotherapy.
• Patients with acute or chronic infectious or inflammatory diseases requiring active treatment with drugs that may interfere with implantation and gestation.
• Chronic treatment with NSAIDs (Nonsteroidal anti-inflammatory drugs)